AVIR Q2 2025 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$2M

Operating Income

-$41M

Net Income

-$37M

EPS (Diluted)

$-0.44

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$392M

Total Liabilities

$27M

Stockholders' Equity

$364M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$2M	-$104,000	-2226.0%
Operating Income	-$41M	-$47M	+11.9%
Net Income	-$37M	-$41M	+8.3%